Results 31 to 40 of about 21,660 (161)

Tumor-induced hypophosphatemia

Indian Journal of Nephrology, 2017
Significant hypophosphatemia is commonly due to Vitamin D deficiency. Any sporadic onset of hypophosphatemia in adults warrants workup to identify alternate causes. Hypophosphatemia may also be the only manifestation of an occult malignancy. A high index of clinical suspicion can help diagnose such conditions in early stages.
K Somani, M Mulani, S Bichu, Vishwanath Billa   +3 more
openaire   +2 more sources

Hypophosphatemia in Intensive Care Unit Canine Patients: Occurrence and Association With Mortality and Duration of Hospitalization

Veterinary Clinical Pathology, EarlyView.
ABSTRACT Background Hypophosphatemia is commonly observed in unselected human intensive care unit (ICU) patients, and it has been associated, although inconsistently, with worse outcomes and longer duration of hospitalization (DOH). The incidence of hypophosphatemia and its association with mortality and DOH in ICU canine patients is unknown ...
Ioannis L. Oikonomidis, Paul Rees, Jorge Hernando Sanz, Glynn Woods   +3 more
wiley   +1 more source

Long-term Observation of Osteomalacia Caused by Adefovir-Induced Fanconi’s Syndrome [PDF]

, 2014
A 64-year-old man suffering polyarthralgia and bone pain was referred to our hospital. Renal dysfunction, hypophosphatemia and increased levels of bone alkaline phosphatase were found.
Ebara, Hirotaka, Hanayama, Yoshihisa, Hidan, Ko, Kawabata, Tomoko, Otsuka, Fumio, Sugiyama, Hitoshi, Takaki, Akinobu, Terasaka, Tomohiro, Ueta, Eijiro, Waseda, Koichi   +9 more
core   +1 more source

Efficacy and safety of JMT103 in patients with bone metastases from solid tumors: A randomized Phase Ib clinical trial

International Journal of Cancer, Volume 156, Issue 11, Page 2178-2187, 1 June 2025.
What's new? Bone metastases are common in a variety of cancer types, causing increased pain and worse outcomes. Suppression of bone turnover, such as with the monoclonal antibody denosumab, results in fewer skeletal complications and improved prognosis. Here, the authors demonstrate the safety and efficacy of a similar antibody, JMT103. Like denosumab,
Ran Ran, Hongtao Li, Tao Sun, Huan Zhou, Aimin Zang, Hongqian Guo, Hua Xie, Shikai Wu, Yong Yan, Xing Yin, Hailin Xiong, Hong Li, Jing Yuan, Juan Wang, Huiping Li, Jin Li   +15 more
wiley   +1 more source

Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. [PDF]

, 2014
Fibroblast growth factor 23 (FGF23) gain of function mutations can lead to autosomal dominant hypophosphatemic rickets (ADHR) disease onset at birth, or delayed onset following puberty or pregnancy. We previously demonstrated that the combination of iron
Albrecht, Marjorie, Allen, Matthew R., Bayt, Christine, Cass, Taryn A., Clinkenbeard, Erica L., Farrow, Emily G., Lahm, Tim, Peacock, Munro, Roberts, Jessica L., Summers, Lelia J., White, Kenneth E.   +10 more
core   +1 more source

Exploring genetic counselors' interest and role in transitional care discussions for pediatric patients with neurodevelopmental conditions

Journal of Genetic Counseling, Volume 34, Issue 3, June 2025.
Abstract Previous studies have examined the perspectives of healthcare providers regarding their role in the transition process of pediatric patients with neurodevelopmental conditions (NDCs), but the perspective of a genetic counselor has yet to be considered.
Molly Lombard, Leah Wetherill, Jennifer Ivanovich, Deborah Hamby, Trisha Neidlinger   +4 more
wiley   +1 more source

Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, Volume 72, Issue 6, June 2025.
ABSTRACT Background Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and although many patients respond to induction therapy, those who relapse or have refractory disease face a poor prognosis. Venetoclax has promising preclinical and clinical activity in ALL.
Andrew E. Place, Seth E. Karol, Christopher J. Forlenza, Todd M. Cooper, Christopher Fraser, Gunnar Cario, Maureen M. O'Brien, Nicolas U. Gerber, Jean‐Pierre Bourquin, Dirk Reinhardt, Jeffrey E. Rubnitz, Joseph T. Opferman, Gauri Sunkersett, Maika Onishi, Diana R. Dunshee, Xin Chen, Kristina Unnebrink, Deeksha Vishwamitra, Fengjiao Dunbar, Mohamed Badawi, Jeremy A. Ross, Mignon L. Loh   +21 more
wiley   +1 more source

Iron deficiency in heart failure: Epidemiology, diagnostic criteria and treatment modalities

ESC Heart Failure, Volume 12, Issue 2, Page 723-726, April 2025.
Stephan von Haehling
wiley   +1 more source

Ferric Carboxymaltose (FCM)–Associated Hypophosphatemia (HPP): A Systematic Review

American Journal of Hematology, Volume 100, Issue 5, Page 840-846, May 2025.
ABSTRACT Background Since 2015, ferric carboxymaltose (FCM), an intravenous (IV) iron formulation used for treating iron deficiency anemia (IDA), has been associated with an increasing number of reported hypophosphatemia (HPP) cases. Information on HPP clinical manifestations and incidence has not been reviewed.
Joseph Magagnoli, Kevin Knopf, William J. Hrushesky, Kenneth R. Carson, Charles L. Bennett   +4 more
wiley   +1 more source

Prévalence et déterminants de l'hypophosphatémie sévère dans un service de Médecine interne [PDF]

, 2012
L'hypophosphatémie sévère définie comme une phosphatémie plasmatique < 0.32 mmol/l (Norme : 0.8-1-4 mmol/l) est associé à une morbidité et mortalité accrues. Il s'agit d'un trouble électrolytique dont la prévalence a été évaluée entre 0.24-0.42 % dans
Zanetti, B.
core